EXPERIMENTAL STUDY

Systemic administration of pituitary adenylate cyclase-activating polypeptide maintains beta-cell mass and retards onset of hyperglycaemia in beta-cell-specific calmodulin-overexpressing transgenic mice

Shin Tsunekawa, Yoshitaka Miura, Naoki Yamamoto, Yuji Itoh¹, Yoh Ariyoshi, Takao Senda², Yutaka Oiso and Ichiro Niki³

Department of Endocrinology and Diabetology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan, ¹Department of Pharmacology, Faculty of Medicine, Oita University, 1-1Hasama, Oita 879-5593, Japan and ²Department of Anatomy I, Fujita Health University, School of Medicine, 1-98 Dengakukakubo, Kutsukake-cho, Toyoake 470-1192, Japan

(Correspondence should be addressed to I Niki; Email: niki@med.oita-u.ac.jp)

Abstract

Objective: Pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to play an important role in the regulation of islet function. We investigated its effects in beta-cell-specific calmodulin-overexpressing diabetic (CaMTg) mice, in which we consider that apoptosis of beta cells is the primary defect leading to basal hyperglycaemia.

Methods: CaMTg mice were treated with continuous s.c. infusions of PACAP from 2 to 4 weeks after birth, and were evaluated against littermate non-transgenic (nTg) and saline-treated CaMTg mice as to plasma glucose levels, insulin content, islet function and morphological features.

Results: Remarkable and progressive hyperglycaemia was observed in CaMTg mice, and PACAP treatment blunted this elevation. Insulin secretion from isolated islets demonstrated an impaired response to glucose in CaMTg mice, and PACAP treatment did not cause any improvement. The total pancreatic insulin content in CaMTg mice decreased significantly to 19.1% of that in nTg mice. PACAP treatment of CaMTg mice increased the content to 158% of the value in saline-treated CaMTg mice. The insulin content in isolated islets from CaMTg mice also decreased to 15.9% of that in nTg mice, while PACAP treatment caused a doubling of the value. Immunohistochemical investigation revealed that the insulin-positive islet area was markedly smaller in CaMTg mice and that PACAP treatment significantly expanded the insulin-positive islet area.

Conclusions: These findings indicate that PACAP treatment retards the onset of hyperglycaemia in CaMTg mice by maintaining beta-cell mass and PACAP treatment may potentially be a therapeutic measure for preventing beta-cell exhaustion during hyperglycaemia.

European Journal of Endocrinology 152 805–811

Introduction

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a ubiquitous neuropeptide belonging to the secretin/glucagon/vasoactive intestinal polypeptide (VIP) superfamily, and exists in two amidated forms, the 38 amino acid residue form (PACAP38) and the truncated 27 residue form (PACAP27). PACAP, originally isolated from the ovine hypothalamus (1), is a multifunctional neuropeptide that acts on a wide variety of cells including neural, immune and endocrine/exocrine cells (2). Although the proportion of PACAP38 to PACAP27 varies among the various organs, these isoforms share the same receptors and are equally potent (3). In endocrine cells, PACAP has been shown to play a positive role in the biosynthesis and release of various hormones, such as luteinising hormone and follicle-stimulating hormone from gonadotrophs, growth hormone (GH) from somatotrophs, catecholamines from the adrenal gland, and insulin and glucagon from pancreatic islets (4). Apart from these actions as secretagogues, both forms of PACAP have been suggested to be involved in the proliferation, growth and survival of cerebellar granule cells and astrocytes (5, 6). PACAP binds three types of G-protein-coupled membrane receptors: PACAP type-1 receptor (PAC1-R), VIP/PACAP subtype-1 receptor (VPAC1-R) and VIP/PACAP subtype-2 receptor (VPAC2-R). PAC1-R is specific to PACAP, whereas VPAC1-R and VPAC2-R do not discriminate between PACAP and VIP. The aforementioned diverse effects of PACAP are due to the wide distribution of the peptide and its receptors, as...
well as to various effectors downstream: adenylate cyclase, phospholipase C, the L-type Ca\(^{2+}\) channel and the mitogen activated protein kinases (7). The insulinotropic effects of PACAP were first reported in mouse islets (8), and this was, then, proved to be due to the activation of VPAC2-R (9), although the involvement of other subtypes of PACAP receptor has been also suggested (10). A recent study demonstrated that daily injections of PACAP reduced blood glucose levels in diabetic Goto-Kakizaki rats, a polygenic model of type 2 diabetes, and high-fat-fed mice, in which the diet is associated with impaired glucose tolerance (11). It has also been documented that a VPAC2-selective agonist peptide, derived from a site-directed mutation of PACAP, increased serum insulin levels and lowered blood glucose in rats (12). Moreover, the beta-cell-specific overexpression of PACAP in vivo enhanced insulin secretion and rendered beta-cells resistant to streptozotocin (13). These findings point to PACAP as an antidiabetic agent. In the present study, we examined the effect of PACAP on the onset of diabetes and its protective effect against beta-cell decay in beta-cell-specific calmodulin-overexpressing transgenic (CaMTg) mice (14, 15), a diabetic animal model with Ca\(^{2+}\)-dependent beta-cell exhaustion (16).

**Materials and methods**

**Minigene construct and the production of transgenic animals**

CaMTg mice, kindly provided by Prof. A R Means (Duke University, Durham, NC, USA), were produced as described previously (14). Briefly, the rat insulin-II promoter/chicken calmodulin cDNA chimeric gene was microinjected into mouse embryos derived from female FVB (Friend leukaemia virus B) mice, followed by the implantation of the embryos into pseudopregnant female FVB mice. The transgenic mice were subsequently bred into the CD1 (caesarean derived 1) strain and later into the ICR (Institute for Cancer Research) strain (16). These mice were housed in a temperature-, humidity- and light-controlled room (21–23°C, 12 h light:12 h darkness cycle) with free access to food and water. They were characterised as having blepharostenosis at 2–3 weeks and frank hyperglycaemia at 4 weeks of age. In cases where earlier characterisation was necessary, genomic typing was carried out (see below). Male CaMTg mice were bred with normal female ICR mice (Japan SLC, Hamamatsu, Japan), because the female CaMTg mice were infertile. As controls, we used non-trangenic (nTg) mice from the same litters. All experiments using laboratory mice were approved by the University Committees on Animal Experiments in accordance with the Guidelines for Animal Experimentation in both Nagoya and Oita Universities.

**PACAP treatment**

Four groups of mice were studied: nTg mice with saline treatment, nTg mice with PACAP treatment, CaMTg mice with saline treatment and CaMTg mice with PACAP treatment. PACAP was purchased from the Peptide Institute (PACAP38; Osaka, Japan). Osmotic mini-pumps (Model 1002; Alzet, Cupertino, CA, USA) were implanted at the end of the second week after birth, and PACAP (40 pmol/g of initial body weight (BW)/day) was s.c. injected during the following 14 days. After the implantation of the osmotic minipumps in the midscapular region, BW and plasma glucose levels were monitored daily. At the end of the experimental period, the pancreases were removed and weighed. For the measurement of the insulin content, pancreas samples were homogenised in ice-cold acid–ethanol solution (0.18 mol/l HCl in 75% ethanol) and centrifuged. The supernatants were diluted and neutralised with 0.1 mol/l Tris-buffered saline (pH 8.0) and subjected to ELISA (Shibayagi, Tokyo, Japan). For the histochemical studies, the pancreases were fixed in 4% paraformaldehyde in 0.1 mol/l phosphate buffer (pH 7.4) and embedded in paraffin.

**Genomic typing by PCR**

Genomic DNA was extracted from the tails of the mice 7 days after birth using the QIAamp DNA Mini Kit (Qiagen), and was subjected to PCR amplification of the chicken calmodulin transgene. The specific primer pairs (sense: 5'-GAGCCACCATGCTGATCA-3'; antisense: 5'-CATGTCTGTAAATCTGGTTGTT-3') amplified a 200 bp product only in CaMTg mice. The results were confirmed by a comparison with the later phenotype of these mice.

**Plasma glucose measurement and i.p. glucose tolerance tests**

Plasma glucose concentrations were measured using a compact glucose analyser (MediSafe; Terumo, Tokyo, Japan). Blood samples were collected by tail cutting in the interval from 1000 to 1400 h from these mice, which were fed freely. I.p. glucose tolerance tests were performed after 8 h of fasting. Glucose (2 mg/g BW) was i.p. injected into 4-week-old CaMTg and nTg mice with or without PACAP treatment.

**The size of the isolated pancreatic islets and insulin release**

Pancreatic islets were isolated from nTg and CaMTg mice with PACAP or saline treatment, using collagenase digestion. The sizes of 100 isolated islets from each experimental group were measured. The effects of PACAP on insulin release were studied using islets from PACAP- and saline-treated CaMTg mice and from PACAP- and saline-treated nTg mice. A group
of three size-matched islets were placed into an incubation tube. After 30 min of preincubation in Hepes-buffered Krebs–Ringer solution (119 mmol/l NaCl, 5.0 mmol/l NaHCO₃, 4.75 mmol/l KCl, 1.2 mmol/l MgSO₄, 2.54 mmol/l CaCl₂, 1.2 mmol/l KH₂PO₄ and 20 mmol/l Hepes, at pH 7.4) containing 0.5% BSA (Fraction V; Sigma) and 3.3 mmol/l glucose (17), the islets were transferred to BSA-containing Hepes-buffered Krebs–Ringer solutions, with a low (3.3 mmol/l) or high (20 mmol/l) concentration of glucose. Both preincubation and incubation were performed at 37 °C in a water bath. Samples were collected after 60 min of incubation for insulin determination with ELISA. The islet insulin content was also measured after ice-cold acid–ethanol extraction, as described above. Data are expressed as the rate of released insulin/islet insulin content.

**Light microscopy and immunohistochemistry**

The pancreases fixed in paraffin blocks were serially sectioned throughout their lengths, in order to avoid any bias from regional changes in islet distribution. The sections were stained with haematoxylin and eosin, and observed by light microscopy. For the immunohistochemical study, the fixed pancreases were washed thoroughly in PBS containing 10, 15 and then 20% sucrose, embedded in Optimal Cutting Temperature (OCT) compound (Sakura, Tokyo, Japan), and frozen. The frozen sections were cut into 5 μm thick slices and incubated for 1 h with anti-insulin guinea pig antibody (Seikagaku Kogyo, Tokyo, Japan) and anti-glucagon rabbit antibody (Zymed, San Francisco, CA, USA). After washing with PBS, they were further incubated for 1 h in a mixture of rhodamine-conjugated anti-guinea pig IgG antibody (ICN, Costa Mesa, CA, USA) and FITC-conjugated anti-rabbit IgG antibody (Vector, Burlingame, CA, USA). The sections were analysed with a confocal scanning laser microscope (MR-1024; Japan Bio-Rad, Tokyo, Japan). The insulin-positive areas were quantitatively evaluated based on 100 islets from each group using NIH Image software.

**Statistical analysis**

Data are expressed as means±S.E. The statistical significance was estimated by Student’s t-test or one-way ANOVA, followed by post-hoc Bonferroni analysis using StatView 5 (SAS Institute, Inc., Cary, NC, USA). A P value of <0.05 was considered statistically significant.

**Results**

**The effects of PACAP on plasma glucose levels**

In nTg mice, plasma glucose levels gradually rose to 7 mmol/l during the first 4 weeks after birth, and PACAP did not exert any appreciable effect on plasma glucose levels. In CaMTg mice, acute and steep elevation of the plasma glucose levels was observed, the levels reaching 15 mmol/l at the end of the experimental period. Continuous and s.c. administration of PACAP apparently blunted the elevation of the plasma glucose levels in CaMTg mice (Fig. 1). The profiles of the gradual increase in BW throughout the period did not differ among these four groups (data not shown), suggesting that the glucose-lowering effects were not due to the suppression of appetite. Serum insulin levels were often undetectable. In the i.p. glucose tolerance tests, sustained hyperglycaemia in CaMTg mice was not influenced by PACAP treatment.

**Islet isolation and insulin secretion experiments**

The yield of islets from CaMTg mice was much lower than that from nTg mice. Light-microscopic observation revealed that isolated islets from CaMTg mice were significantly smaller than those from nTg mice. PACAP treatment stabilised the size of the isolated islets in CaMTg mice (92.2±2.5 μm for nTg/saline, 101.3±2.1 μm for nTg/PACAP, 63.9±2.3 μm for CaMTg/saline and 76.3±3.5 μm for CaMTg/PACAP) (Fig. 2), although the yield was similar to that of saline-treated CaMTg mice. PACAP treatment did not alter the size and yield of the islets in nTg mice. In the secretion experiments, the basal levels of insulin secretion from CaMTg islets with or without PACAP treatment were much lower than those from nTg islets (Fig. 3). However, when expressed as the rate of released insulin/insulin content, the value for PACAP-treated CaMTg islets was apparently higher than that...
for saline-treated CaMTg islets. The islets from nTg mice showed an 8.9-fold increase of insulin secretion by 20 mmol/l glucose, while those from saline-treated CaMTg mice failed to respond to 20 mmol/l glucose. PACAP treatment did not improve the response of CaMTg islets to glucose.

**The effects of PACAP on the pancreatic insulin content**

As shown in Fig. 4, pancreatic insulin content in CaMTg mice was significantly lower (74.5% of the content in saline-treated nTg mice at the age of 2 weeks), although nTg and CaMTg mice did not differ in their plasma glucose concentrations. The insulin content in nTg mice increased with age, while the increase with age was minimal in CaMTg mice; the content in CaMTg mice was only 19.1% of that in nTg mice at the end of the experimental period. Following this reduction in the insulin reserves, the progression to hyperglycaemia occurred. PACAP treatment had no effect on the insulin content in nTg mice (102.5% of the content in saline-treated nTg mice), but it boosted the pancreatic insulin content in CaMTg mice to 277 and 158% of the content in saline-treated CaMTg mice after 1 and 2 weeks of treatment respectively.

**The effects of PACAP treatment on insulin content in isolated pancreatic islets**

The insulin content in isolated islets from 4-week-old CaMTg mice was 15.9% of that from nTg mice of the same age (84.0 ± 5.3 ng/islet for nTg and 13.3 ± 2.9 ng/islet for CaMTg). In nTg islets, PACAP treatment did not change the insulin content, while in CaMTg islets it markedly increased the insulin content to 213% of the saline-treated CaMTg islet value. Thus, the PACAP-induced increase of insulin content in islets may be involved in the glucose-lowering effects of PACAP in CaMTg mice.

**Histological and morphometrical studies**

Haematoxylin and eosin staining revealed very small CaMTg pancreatic islets, and PACAP treatment apparently increased their size and number. The pancreatic islets in saline-treated nTg mice were round in shape, whereas those from saline-treated CaMTg mice were irregular in outline (Fig. 5a and d, and b and e). The sizes of the individual CaMTg islet cells were apparently small, while the sizes of the nuclei were similar, indicating that the decrease was due to the reduction in cytoplasmic volume. PACAP treatment attenuated these morphological changes (Fig. 5c and f). Immunohistochemical study demonstrated a good organisation of the islet endocrine cells in nTg mice, with a central core of beta cells and a peripheral array of alpha cells (Fig. 6a). A marked decrease in insulin-positive cells was observed in the islets from CaMTg mice with the destruction of the organisation of the endocrine cells.
(Fig. 6b). PACAP treatment enlarged both the insulin- and the glucagon-immunopositive regions (Fig. 6c and d), although PACAP treatment had no effect on the spatial derangement of the endocrine cells in the islets. Statistical analysis with 100 islets from three mice from each group revealed that PACAP treatment significantly expanded the insulin-positive area in CaMTg mice (Fig. 7).

**Discussion**

We previously found that a Ca$^{2+}$/calmodulin-dependent and constitutive isoform of nitric oxide synthase (NOS) was present in beta cells, and that the time-dependent beta-cell decay in CaMTg mice was partially prevented by daily i.p. injections of the NOS inhibitor N$^\text{ω}$-nitro-L-arginine methyl ester (L-NAME) (16). We here demonstrate that chronic and systemic administration of PACAP more consistently retards progression to diabetes in CaMTg mice than L-NAME did.

The antidiabetic effects of PACAP, also reported in other diabetic models, were mostly interpreted as a result of its potent insulinotropic effect on the beta cell. The present findings, however, suggest to us...
that the beneficial effects of PACAP are mainly due to its protective effect on beta-cell mass rather than its direct effect on the secretory process, firstly because PACAP treatment did not improve the impaired insulin response to glucose stimulation from isolated CaMTg islets, and secondly because the serum insulin levels in CaMTg mice were not altered by the treatment. However, we cannot entirely eliminate the possibility that PACAP did increase in vivo insulin release in CaMTg mice but within an undetected range. The effect of PACAP on beta-cell mass could be explained by its prevention of the reduction of beta-cells (apoptosis) and/or its activation of beta-cell proliferation and neogenesis. We speculate that the protection of beta cells from apoptosis is more relevant for the PACAP action, because PACAP treatment failed to influence beta-cell mass and the pancreatic insulin content in nrg mice in the present study. This is consistent with a recent report that beta-cell-specific overexpression of PACAP in vivo not only potentiated insulin secretion but also rendered beta cells resistant to streptozotocin (13). Extrapancreatic effects may also participate in the antiadipogenic actions, because PACAP is reported to increase glucose uptake into cultured adipocytes (18).

It should be noted that other hormones or pharmacological substances which elevate cAMP levels also protect beta cells against apoptotic cell death. Glucagon-like peptide 1 and its lizard homologue, exendin-4, are known to possess a highly potent insulinotrophic effect, and to stimulate cAMP production in the beta-cell by activating adenylate cyclase. Chronic treatment with these substances has been reported to improve hyperglycaemia in diabetic animals as well as in human diabetic subjects, but increased serum insulin levels are not always associated with such treatments (19–21). In in vitro studies, these substances are reported to possess protective effects against beta-cell death caused by various types of cell toxicity, including combinations of cytokines, where NO plays a critical role in beta-cell apoptosis (22–24).

We have previously reported that PACAP reduced the rate of cytokine-induced apoptosis in cultured beta TC insulinoma cells (25). These findings were originally interpreted as a result of the inhibition of inducible NOS expression. However, suppression of the enzymatic activity or the subsequent apoptotic processes might also be involved in the prevention of beta-cell apoptosis by PACAP.

Relatively little information is available on the molecular mechanisms involved in the expansion of beta-cell mass. Some molecules implicated in insulin signalling, such as insulin receptor substrate (IRS) proteins and Akt/protein kinase B, have been reported to participate in beta-cell survival (26). We have very limited knowledge of the cAMP-dependent control of beta-cell mass. In this respect, a recent study indicating that induction of IRS-2 by cAMP signalling via phosphorylation of CREB may prevent beta-cell apoptosis is highly interesting (27).

Acknowledgements

The authors are grateful to Prof. A R Means (Duke University) for his generous gift of the CaMTg mice used in this study. This work was supported in part by two Grants-in-Aid for Scientific Research (Nos 13671183 and 13470006) from the Japan Society for the Promotion of Science, a research grant from the Japan Insulin Study Group, a grant from the Research for the Future Program of the Japan Society for the Promotion of Science (JSPS-RFTF97100201), and by grants from the Japan Research Foundation for Clinical Pharmacology and from the Suzuken Memorial Foundation.

References


